The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Milnacipran Pierre Fabre Medicament milnacipran | Pierre Fabre Medicament | Fibromyalgia | 🇪🇺 EU 2009-11-19 | Order → |
| Miplyffa arimoclomol Orphan | Orphazyme A/S | Niemann-Pick Disease, Type C | 🇪🇺 EU | Order → |
| Movectro cladribine | Merck Serono Europe Limited | Multiple Sclerosis | 🇪🇺 EU | Order → |
| Mulsevo semuloparin sodium | Sanofi-aventis groupe | 🇪🇺 EU | Order → | |
| Multaq dronedarone | Sanofi-Aventis | Atrial Fibrillation; Atrial Flutter | 🇪🇺 EU | Order → |
| Mycograb efungumab | NeuTec Pharma plc | Candidiasis | 🇪🇺 EU 2007-03-20 | Order → |
| Mylotarg gemtuzumab ozogamicin Orphan | Wyeth Europa Ltd | Leukemia, Myeloid, Acute | 🇪🇺 EU 2008-01-24 | Order → |
| Natalizumab Elan Pharma natalizumab | Elan Pharma International Ltd. | Crohn Disease | 🇪🇺 EU 2007-11-15 | Order → |
| Neffy epinephrine | Ars Pharmaceuticals Irl Limited | Hypersensitivity; Anaphylaxis | 🇪🇺 EU | Order → |
| Nenad lisuride | Axxonis Pharma AG | Restless Legs Syndrome | 🇪🇺 EU | Order → |
| Neocepri folic acid | Endocyte Europe, B.V. | Ovarian Neoplasms; Radionuclide Imaging | 🇪🇺 EU | Order → |
| Neofordex dexamethasone | Laboratoires CTRS - Boulogne Billancourt | Multiple Myeloma | 🇪🇺 EU | Order → |
| Nerventra laquinimod | Teva Pharma GmbH | Multiple Sclerosis | 🇪🇺 EU 2014-05-22 | Order → |
| Neuzafy filgrastim Biosimilar | CuraTeQ Biologics (Malta) Limited | Neutropenia; Febrile Neutropenia; Chemotherapy-Induced Febrile Neutropenia | 🇪🇺 EU 2026-10-15 | Order → |
| Nezglyal leriglitazone Orphan | Minoryx Therapeutics S.L. | Adrenoleukodystrophy | 🇪🇺 EU 2024-05-28 | Order → |
| Nidlegy bifikafusp alfa;onfekafusp alfa | Philogen S.p.A. | Melanoma | 🇪🇺 EU | Order → |
| Nouryant istradefylline | Kyowa Kirin Holdings B.V. | Parkinson Disease | 🇪🇺 EU 2021-07-22 | Order → |
| Nugalviq govorestat Orphan | Advanz Pharma Limited | Galactosemias | 🇪🇺 EU | Order → |
| Nurzigma pridopidine Orphan | Prilenia Therapeutics B.V. | Huntington Disease | 🇪🇺 EU 2025-07-24 | Order → |
| Nuzyra | Paratek Ireland Limited | Pneumonia, Bacterial; Skin Diseases, Bacterial | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.